Transcutaneous immunization of Streptococcus suis bacterin using dissolving microneedles

Hsueh, Kai Jen; Chen, Mei-Chin; Cheng, Li Ting; Lee, Jai Wei; Chung, Wen Bin; Chu, Chun Yen

doi:10.1016/j.cimid.2016.12.001

Cited by 10 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…or i.d. vaccination in a number of applications (DeMuth et al, 2014;Hsueh et al, 2017;Kim et al, 2009). In this study coated MNs were used to deliver a vaccine payload in a 'dried form'.…”

Section: Discussionmentioning

confidence: 99%

Skin vaccination using microneedles coated with a plasmid DNA cocktail encoding nucleosomal histones of Leishmania spp.

Moreno

Schwartz

Calvo

et al. 2017

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Vaccine delivery using microneedles (MNs) represents a safe, easily disposable and painless alternative to traditional needle immunizations. The MN delivery of DNA vaccines to the dermis may result in a superior immune response and/or an equivalent immune response at a lower vaccine dose (dose-sparing). This could be of special interest for immunization programs against neglected tropical diseases such as leishmaniasis. In this work, we loaded a MN device with 60μg of a plasmid DNA cocktail encoding the Leishmania infantum nucleosomal histones H2A, H2B, H3 and H4 and compared its immunogenicity and protective capacity against conventional s.c. or i.d. injection of the plasmid. Mice immunized with MNs showed increased ratios of IFN-γ/IL-10, IFN-γ/IL-13, IFN-γ/IL-4, and IFN-γ/TGF-β in the spleens and lymph nodes compared with mice immunized by s.c. and i.d. routes. Furthermore, CCXCL9, CXCL10 and CCL2 levels were also higher. These data suggest that the nucleic acid immunization using MNs produced a better bias towards a Th1 response. However, none of the immunizations strategies were able to control Leishmania major infection in BALB/c mice, as illustrated by an increase in lesion size and parasite burden.

show abstract

“…or i.d. vaccination in a number of applications (DeMuth et al, 2014;Hsueh et al, 2017;Kim et al, 2009). In this study coated MNs were used to deliver a vaccine payload in a 'dried form'.…”

Section: Discussionmentioning

confidence: 99%

Skin vaccination using microneedles coated with a plasmid DNA cocktail encoding nucleosomal histones of Leishmania spp.

Moreno

Schwartz

Calvo

et al. 2017

International Journal of Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Real-time PCR cytokine analysis: isolation of splenocytes from mice . Isolation of spleen cells was carried out as described ( 11 ). Briefly, spleen samples from each mouse were individually homogenised in a 40-μm stainless steel tissue grinder in Roswell Park Memorial Institute 1640 medium (RPMI 1640; Gibco, Grand Island, NY, USA) supplemented with 2 mM L-glutamine, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, sodium bicarbonate (2.2 g/L) and gentamicin (50 μg/mL).…”

Section: Methodsmentioning

confidence: 99%

Recombinant hexon protein as a new bovine adenovirus type 3 subunit vaccine candidate

Gundegmaa¹,

Odbileg

et al. 2023

Journal of Veterinary Research

Self Cite

View full text Add to dashboard Cite

Introduction Bovine adenovirus (BAdV) type 3 causes respiratory and gastroenteric diseases of varying severity in cattle, particularly newborn calves. Trials have been conducted of a vaccination against the diseases caused by BAdV using both modified live-virus and inactivated-virus preparations in cattle, but no commercial BAdV-3 vaccine has yet reached the market. Therefore, there is an urgent need to develop new, safe, and effective vaccines against BAdV-3. Material and Methods Recombinant hexon protein (rhexon) of BAdV-3 was expressed in the E. coli system to evaluate immune response in mice and goats. Antibody responses and cytokine levels were analysed and the effects of administrations of different amounts of recombinant protein compared. Long-term antibody production was evaluated by indirect ELISA, and the total immunoglobulin G secreted by goats and mice immunised with the purified rhexon protein was determined. Results The immunised mice had a stronger antibody response than the control group at eight weeks post vaccination. The immunised groups also showed significantly higher (P ˂ 0.05) expression of interferon-γ, interleukin 2 (in mice), and interleukin 21 (in goats) at four weeks. Furthermore, vaccination with rhexon was able to induce long-term antibody production for at least 16 weeks in mice and goats. Conclusion The rhexon protein induced immune responses, especially long-term antibody production and T helper 1 cell cytokine production in mice and goats. The immunogenic properties of this protein make it a promising subunit vaccine antigen.

show abstract

“…53 Vaccine development for bacteria-derived pathogens plays a critical role in decreasing the burden on the health-care system throughout the world. Several such severe antigens were researched to be delivered by MAP, and mice were challenged after vaccination to prove the strong induction of protective immunity against Pseudomonas aeruginosa, 122 Clostridium difficile, 107 Streptococcus suis, 118 and Francisella novicida. 88 The anthrax vaccine was tested, and the results showed 100% protection from aerosol spore challenge in rabbits.…”

Section: Preclinical Studies Of Vaccine Mapmentioning

confidence: 99%

Progress in microneedle array patch (MAP) for vaccine delivery

Nguyen

Kim

et al. 2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

A microneedle array patch (MAP) has been developed as a new delivery system for vaccines. Preclinical and clinical trials with a vaccine MAP showed improved stability, safety, and immunological efficacy compared to conventional vaccine administration. Various vaccines can be delivered with a MAP. Currently, microneedle manufacturers can mass-produce pharmaceutical MAP and cosmetic MAP and this mass-production system can be adapted to produce a vaccine MAP. Clinical trials with a vaccine MAP have shown comparable efficacy with conventional administration, and discussions about regulations for a vaccine MAP are underway. However, there are concerns of reasonable cost, mass production, efficacy, and safety standards that meet FDA approval, as well as the need for feedback regarding the best method of administration. Currently, microneedles have been studied for the delivery of many kinds of vaccines, and preclinical and clinical studies of vaccine microneedles are in progress. For the foreseeable future, some vaccines will continue to be administered with syringes and needles while the use of a vaccine MAP continues to be improved because of the advantages of less pain, self-administration, improved stability, convenience, and safety.

show abstract

Transcutaneous immunization of Streptococcus suis bacterin using dissolving microneedles

Cited by 10 publications

References 29 publications

Skin vaccination using microneedles coated with a plasmid DNA cocktail encoding nucleosomal histones of Leishmania spp.

Skin vaccination using microneedles coated with a plasmid DNA cocktail encoding nucleosomal histones of Leishmania spp.

Recombinant hexon protein as a new bovine adenovirus type 3 subunit vaccine candidate

Progress in microneedle array patch (MAP) for vaccine delivery

Contact Info

Product

Resources

About